
1. j infect dis. 2013 mar 1;207(5):759-67. doi: 10.1093/infdis/jis752. epub 2012 dec
7.

predictors cd4(+) t-cell counts hiv type 1-infected persons virologic
failure 3 original antiretroviral drug classes.

pursuing later treatment option ii (plato ii) project team collaboration
of observational hiv epidemiological research europe (cohere), costagliola d,
ledergerber b, torti c, van sighem a, podzamczer d, mocroft a, dorrucci m,
masquelier b, de luca a, jansen k, de wit s, obel n, fätkenheuer g, touloumi g,
mussini c, castagna a, stephan c, garcía f, zangerle r, duval x, perez-hoyos s,
meyer l, ghosn j, fabre-colin c, kjaer j, chêne g, grarup j, phillips a, lodwick 
r, torti c, dorrucci m, günthard hf, michalik c, chrysos g, castagna a.

collaborators: audelin a, castagna a, costagliola d, cozzi-lepri a, de luca a, de
wit s, de wolf f, dorrucci m, duval x, fätkenheuer g, garcía f, ghosn j, günthard
h, jansen k, judd a, ledergerber b, lo caputo s, lodwick r, masquelier b, meyer
l, mocroft a, mussini c, noguera-julian a, obel n, paraskevis d, paredes r,
pérez-hoyos s, phillips a, pillay d, podzamczer d, ramos jt, stephan c, tookey
pa, torti c, touloumi g, van sighem a, warsawski j, zangerle r, zangerle r,
touloumi g, warszawski j, meyer l, dabis f, krause mm, ghosn j, leport c, de wolf
f, reiss p, prins m, bucher h, sabin c, gibb d, fätkenheuer g, del amo j, obel n,
thorne c, mocroft a, kirk o, stephan c, pérez-hoyos s, noguera-julian a, antinori
a, d'arminio monforte a, brockmeyer n, ramos j, battegay m, rauch a, mussini c,
tookey p, casabona j, miró jm, castagna a, de wit s, goetghebuer t, torti c,
teira r, garrido m, haerry d, weller i, casabona j, costagliola d,
d'arminio-monforte a, battegay m, prins m, de wolf f, grarup j, chene g, bohlius 
j, bouteloup v, bucher h, cozzi-lepri a, dabis f, de wolf f, dorrucci m, egger m,
engsig f, furrer h, kirk o, lambotte o, lewden c, lodwick r, matheron s, meyer l,
miro j, mocroft a, obel n, paredes r, phillips a, puoti m, reekie j, sabin c,
scherrer a, smit c, sterne j, thiebaut r, thorne c, torti c, von wyl v, wittkop
l, scherrer a, smit c, sterne j, thiebaut r, thorne c, torti c, von wyl v,
wittkop l.

background: low cd4(+) t-cell counts main factor leading clinical
progression human immunodeficiency virus type 1 (hiv-1) infection. aimed to
investigate factors affecting cd4(+) t-cell counts triple-class virological
failure.
methods: included individuals cohere database started
antiretroviral therapy 1998 onward experienced triple-class
virological failure. cd4(+) t-cell counts obtained triple-class virologic
failure analyzed using generalized estimating equations.
results: analyses included 2424 individuals total 23 922 cd4(+)
t-cell count measurements. adjusted models (excluding current viral load and
year), cd4(+) t-cell counts higher regimens included boosted
protease inhibitors (increase, 22 cells/µl [95% confidence interval {ci},
3.9-41]; p = .017) drugs new classes (increase, 39 cells/µl [95% ci, 
15-62]; p = .001), compared nonnucleoside reverse-transcriptase
inhibitor-based regimens. associations disappeared current viral load 
and/or calendar year included. compared viral levels <2.5 log(10)
copies/ml, levels 2.5-3.5, 3.5-4.5, 4.5-5.5, >5.5 log(10) copies/ml were
associated cd4(+) t-cell count decreases 51, 84, 137, 186 cells/µl,
respectively (p < .001).
conclusions: approximately linear inverse relationship log(10) viral 
load cd4(+) t-cell count indicates likely immunologic benefits
from lowering viral load even modest amounts lead undetectable 
viral loads. important patients low cd4(+) t-cell counts few
drug options.

doi: 10.1093/infdis/jis752 
pmid: 23225900  [indexed medline]

